Nasal airflow in growth hormone treatment.

Abstract

Nasal congestion due to hormonal influences has been recognized as a clinical entity, and a "hormonal rhinitis" has been proposed to occur in acromegaly. In this study we investigated the effect of low-dose recombinant human growth hormone over eight weeks on nasal congestion as measured by nasal peak flow in a randomized, placebo-controlled, double-blind crossover clinical trial in ten patients with short bowel syndrome. The treatment did not induce a significant nasal congestion. Whether higher doses as used in many catabolic conditions do remains to be determined.

• Authors: E Ellegård, L Ellegård
• Journal: Rhinology (Rhinology) Vol. 36 Issue 2 Pg. 66-8 (Jun 1998) ISSN: 0300-0729 [Print] Netherlands
• PMID: 9695160 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Growth Hormone

Topics

• Adult
• Aged
• Cross-Over Studies
• Double-Blind Method
• Female
• Growth Hormone (therapeutic use)
• Humans
• Male
• Middle Aged
• Nasal Cavity (physiopathology)
• Nasal Obstruction (drug therapy, etiology, physiopathology)
• Peak Expiratory Flow Rate
• Short Bowel Syndrome (complications)
• Treatment Outcome